



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

DDI1 siRNA (m): sc-142917

BACKGROUND

DDI1 and DDI2 are ubiquitin receptor homologs of the *Saccharomyces cerevisiae* ddi1 protein, which is involved in regulation of the cell cycle and the late secretory pathway. DDI1 is a 396 amino acid protein that contains one ubiquitin-like domain. The gene encoding DDI1 maps to human chromosome 11, which makes up around 4% of human genomic DNA and is considered a gene and disease association dense chromosome. The chromosome 11 encoded Atm gene is important for regulation of cell cycle arrest and apoptosis following double strand DNA breaks. Atm mutation leads to the disorder known as ataxia-telangiectasia. The blood disorders Sickle cell anemia and β thalassemia are caused by HBB gene mutations. Wilms' tumors, WAGR syndrome and Denys-Drash syndrome are associated with mutations of the WT1 gene.

REFERENCES

1. Grossfeld, P.D., Mattina, T., Lai, Z., Favier, R., Jones, K.L., Cotter, F. and Jones, C. 2004. The 11q terminal deletion disorder: a prospective study of 110 cases. *Am. J. Med. Genet. A* 129A: 51-61.
2. Loussouarn, G., Baró, I. and Escande, D. 2006. KCNQ1 K⁺ channel-mediated cardiac channelopathies. *Methods Mol. Biol.* 337: 167-183.
3. Taylor, T.D., Noguchi, H., Totoki, Y., Toyoda, A., Kuroki, Y., Dewar, K., Lloyd, C., Itoh, T., Takeda, T., Kim, D.W., She, X., Barlow, K.F., Bloom, T., Bruford, E., Chang, J.L., Cuomo, C.A., Eichler, E., Fitzgerald, M.G., Jaffe, D.B., et al. 2006. Human chromosome 11 DNA sequence and analysis including novel gene identification. *Nature* 440: 497-500.
4. Zehelein, J., Kathoefer, S., Khalil, M., Alter, M., Thomas, D., Brockmeier, K., Ulmer, H.E., Katus, H.A. and Koenen, M. 2006. Skipping of exon 1 in the KCNQ1 gene causes Jervell and Lange-Nielsen syndrome. *J. Biol. Chem.* 281: 35397-35403.
5. Ataga, K.I., Cappellini, M.D. and Rachmilewitz, E.A. 2007. β -thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. *Br. J. Haematol.* 139: 3-13.
6. Berger, A.C., Salazar, G., Styers, M.L., Newell-Litwa, K.A., Werner, E., Maue, R.A., Corbett, A.H. and Faundez, V. 2007. The subcellular localization of the Niemann-Pick type C proteins depends on the adaptor complex AP-3. *J. Cell Sci.* 120: 3640-3652.
7. Lee, J.H. and Paull, T.T. 2007. Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. *Oncogene* 26: 7741-7748.
8. O'Connor, M.J., Martin, N.M. and Smith, G.C. 2007. Targeted cancer therapies based on the inhibition of DNA strand break repair. *Oncogene* 26: 7816-7824.
9. Kaste, S.C., Dome, J.S., Babyn, P.S., Graf, N.M., Grundy, P., Godzinski, J., Levitt, G.A. and Jenkinson, H. 2008. Wilms' tumour: prognostic factors, staging, therapy and late effects. *Pediatr. Radiol.* 38: 2-17.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.

CHROMOSOMAL LOCATION

Genetic locus: Ddi1 (mouse) mapping to 9 A1.

PRODUCT

DDI1 siRNA (m) is a pool of 3 target-specific 19-25 nt siRNAs designed to knock down gene expression. Each vial contains 3.3 nmol of lyophilized siRNA, sufficient for a 10 μ M solution once resuspended using protocol below. Suitable for 50-100 transfections. Also see DDI1 shRNA Plasmid (m): sc-142917-SH and DDI1 shRNA (m) Lentiviral Particles: sc-142917-V as alternate gene silencing products.

For independent verification of DDI1 (m) gene silencing results, we also provide the individual siRNA duplex components. Each is available as 3.3 nmol of lyophilized siRNA. These include: sc-142917A, sc-142917B and sc-142917C.

STORAGE AND RESUSPENSION

Store lyophilized siRNA duplex at -20° C with desiccant. Stable for at least one year from the date of shipment. Once resuspended, store at -20° C, avoid contact with RNases and repeated freeze thaw cycles.

Resuspend lyophilized siRNA duplex in 330 μ l of the RNase-free water provided. Resuspension of the siRNA duplex in 330 μ l of RNase-free water makes a 10 μ M solution in a 10 μ M Tris-HCl, pH 8.0, 20 mM NaCl, 1 mM EDTA buffered solution.

APPLICATIONS

DDI1 siRNA (m) is recommended for the inhibition of DDI1 expression in mouse cells.

SUPPORT REAGENTS

For optimal siRNA transfection efficiency, Santa Cruz Biotechnology's siRNA Transfection Reagent: sc-29528 (0.3 ml), siRNA Transfection Medium: sc-36868 (20 ml) and siRNA Dilution Buffer: sc-29527 (1.5 ml) are recommended. Control siRNAs or Fluorescein Conjugated Control siRNAs are available as 10 μ M in 66 μ l. Each contain a scrambled sequence that will not lead to the specific degradation of any known cellular mRNA. Fluorescein Conjugated Control siRNAs include: sc-36869, sc-44239, sc-44240 and sc-44241. Control siRNAs include: sc-37007, sc-44230, sc-44231, sc-44232, sc-44233, sc-44234, sc-44235, sc-44236, sc-44237 and sc-44238.

RT-PCR REAGENTS

Semi-quantitative RT-PCR may be performed to monitor DDI1 gene expression knockdown using RT-PCR Primer: DDI1 (m)-PR: sc-142917-PR (20 μ l). Annealing temperature for the primers should be 55-60° C and the extension temperature should be 68-72° C.

RESEARCH USE

For research use only, not for use in diagnostic procedures.